A Phase II Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT). An allogeneic hematopoietic cell transplantation (allo-HCT) is a treatment in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. When healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving ibrutinib after the transplant may stop that from happening. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking a protein in the blood called Bruton's tyrosine kinase (BTK). By blocking BTK, ibrutinib inhibits certain immune cells that play a role in cGVHD. Giving ibrutinib after an allo-HCT may prevent the development of chronic GVHD.

开始日期2024-11-01

申办/合作机构

Mayo Clinic

NCT06536049 / Not yet recruiting临床1/2期

Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to two different types of receptors (proteins present on the cell surface) at the same time. The two receptors that epcoritamab binds to are called CD3 and CD20. CD3 is found on T cells, which are important cells of the immune system that help fight cancer and infections. CD20 is found on the surface of most types of aggressive B-cell non-Hodgkin lymphoma cells. By binding to both CD3 and CD20, epcoritamab brings the two cells close together so the T cells can fight and kill the lymphoma B cells. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, binds to a protein on B cells, a type of white blood cell from which the lymphoma developed. By doing this it decreases the ability of the lymphoma B cells to survive and grow. Ibrutinib may also improve the health (or fitness) of T cells thus making epcoritamab safer and/or more effective.

开始日期2024-10-31

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+2]

IRCT20200105046010N111 / Recruiting

In-vivo Bioequivalence Study of Ibrutinib 140 mg capsule of The Test Drug (ACTLOUVIKA®, 140 mg ., Actero Pharma, Iran) in Compared with The Reference Drug (IMBRUVICA® 140 mg ., Jenssen Inc. Swiss) In Iranian Healthy Volunteers

开始日期2024-08-22

申办/合作机构-

100 项与伊布替尼相关的临床结果

登录后查看更多信息

100 项与伊布替尼相关的转化医学

登录后查看更多信息

100 项与伊布替尼相关的专利（医药）

登录后查看更多信息

3,542

项与伊布替尼相关的文献（医药）

2024-05-01·The Journal of allergy and clinical immunology

BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria

Review

作者: Maurer, Marcus ; Saini, Sarbjit S ; Bernstein, Jonathan A

Chronic spontaneous urticaria (CSU) is an inflammatory skin disorder that manifests with itchy wheals, angioedema, or both for more than 6 weeks. Mast cells and basophils are the key pathogenic drivers of CSU; their activation results in histamine and cytokine release with subsequent dermal inflammation. Two overlapping mechanisms of mast cell and basophil activation have been proposed in CSU: type I autoimmunity, also called autoallergy, which is mediated via IgE against various autoallergens, and type IIb autoimmunity, which is mediated predominantly via IgG directed against the IgE receptor FcεRI or FcεRI-bound IgE. Both mechanisms involve cross-linking of FcεRI and activation of downstream signaling pathways, and they may co-occur in the same patient. In addition, B-cell receptor signaling has been postulated to play a key role in CSU by generating autoreactive B cells and autoantibody production. A cornerstone of FcεRI and B-cell receptor signaling is Bruton tyrosine kinase (BTK), making BTK inhibition a clear therapeutic target in CSU. The potential application of early-generation BTK inhibitors, including ibrutinib, in allergic and autoimmune diseases is limited owing to their unfavorable benefit-risk profile. However, novel BTK inhibitors with improved selectivity and safety profiles have been developed and are under clinical investigation in autoimmune diseases, including CSU. In phase 2 trials, the BTK inhibitors remibrutinib and fenebrutinib have demonstrated rapid and sustained improvements in CSU disease activity. With phase 3 studies of remibrutinib ongoing, it is hoped that BTK inhibitors will present an effective, well-tolerated option for patients with antihistamine-refractory CSU, a phenotype that presents a considerable clinical challenge.

2024-03-12·Blood advances

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Article

作者: Linton, Kim ; Ediriwickrema, Kushani ; Mohamedbhai, Sajir ; Prahladan, Mahesh ; Nga, Emma ; Talbot, Georgina ; Webb, Amy ; Fowler, Nicole ; Jackson, Barry ; Camacho, Raisa Guerrero ; Beech, Amy ; Crosbie, Nicola ; Wilson, Marketa ; Walter, Harriet ; Dukka, Vasavi ; Nicholson, Toby ; Shotton, Rohan ; Marr, Helen ; Lord, Angela ; Norman, Jane ; Stern, Simon ; Thomas, Nicky ; Pillai, Arvind ; Phillips, Neil ; Lowry, Lisa ; Rees, Clare ; Eyre, Toby A ; Santarsieri, Anna ; Jones, Steve ; Virchis, Andres ; Burney, Claire ; Sutton, Taylor ; Zhao, Rui ; Stanton, Louise ; Everden, Angharad ; Bishton, Mark ; Lewis, David ; Owen, Mary ; Flont, Marcin ; Hodson, Andrew ; Qureshi, Iman ; Allchin, Rebecca ; Goddard, Jack ; Tucker, David ; Wright, Josh ; Willimott, Victoria ; Lambert, Jonathan ; Paneesha, Shankara ; Koppana, Manasvi ; Bedford, Claudia ; McCulloch, Rory ; Hildyard, Catherine ; Smith, Susan ; Reeve, Miriam ; Miall, Fiona ; Davies, Elizabeth ; Wilson, Jamie ; Tivey, Ann ; Moule, Simon ; Wrench, David ; Protheroe, Sam ; Bailey, James ; Maddox, Jamie ; Sharpley, Faye ; Chaturvedi, Anshuman ; Gibb, Adam ; Knott, Chloe ; Swe, Wunna

Abstract:

During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high-risk, and 8.9% autologous transplant candidates. All patients received ≥1 cycle ibrutinib (median, 8 cycles), 39.0% with rituximab. Grade ≥3 toxicity occurred in 20.3%, and 33.8% required dose reductions/delays. At 15.6-month median follow-up, 41.6% discontinued ibrutinib, 8.1% due to toxicity. Of 104 response-assessed patients, overall (ORR) and complete response (CR) rates were 71.2% and 20.2%, respectively. ORR was 77.3% (low risk) vs 59.0% (high risk) (P = .05) and 78.7% (ibrutinib-rituximab) vs 64.9% (ibrutinib; P = .13). Median progression-free survival (PFS) was 26.0 months (all patients); 13.7 months (high risk) vs not reached (NR) (low risk; hazard ratio [HR], 2.19; P = .004). Median overall survival was NR (all); 14.8 months (high risk) vs NR (low risk; HR, 2.36; P = .005). Median post-ibrutinib survival was 1.4 months, longer in 41.9% patients receiving subsequent treatment (median, 8.6 vs 0.6 months; HR, 0.36; P = .002). Ibrutinib with or without rituximab was effective and well tolerated as first-line treatment of MCL, including older and transplant-ineligible patients. PFS and OS were significantly inferior in one-third of patients with high-risk disease and those unsuitable for post-ibrutinib treatment, highlighting the need for novel approaches in these groups.

2024-03-01·Journal of managed care & specialty pharmacy

Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations

Article

作者: Ballreich, Jeromie ; Odouard, Ilina C ; Alexander, G Caleb ; Anderson, Gerard F

BACKGROUND:

The 2022 Inflation Reduction Act authorizes Medicare to negotiate the prices of 10 drugs in 2026 and additional drugs thereafter. Understanding the sociodemographic and spending characteristics of beneficiaries taking these specific drugs could be important describing the impact of the legislation.

OBJECTIVE:

To describe sociodemographic and spending characteristics of Medicare beneficiaries who use the 10 prescription drugs ("negotiated drugs") that will face Medicare drug price negotiations in 2026.

METHODS:

A 20% sample of Medicare Part D beneficiaries from 2020 (n = 10,224,642) was used. Sociodemographic and spending characteristics were descriptively reported for beneficiaries taking the negotiated drugs, including subgroups by low-income subsidy (LIS) status and by drug, and for Part D beneficiaries not taking negotiated drugs.

RESULTS:

Part D beneficiaries taking a negotiated drug compared with Part D beneficiaries not taking a negotiated drug overall had similar sociodemographic characteristics, more comorbidities (3.9 vs 2.2) and higher mean [median] Medicare ($33,882 [$18,251] vs $12,366 [$3,429]) and out-of-pocket (OOP) spending ($813 [$307] vs $441 [$160]). There was variation in characteristics by LIS status. The mean age was highest among non-LIS beneficiaries taking a negotiated drug compared with LIS beneficiaries taking a negotiated drug and beneficiaries not taking a negotiated drug (76.2 vs 69.9 vs 71.4). Among beneficiaries using negotiated drugs, a higher percentage of LIS beneficiaries compared with non-LIS was female (59.7% vs 48.0%), was Black (20.9% vs 6.6%), and resided in lower-income areas (39.1% vs 20.3%). Mean [median] annual Part D OOP spending for negotiated drugs was $115 [$59] for beneficiaries with LIS and $1,475 [$1,204] for beneficiaries without LIS. There were also differences depending on which negotiated drug was used. Drugs for cancer and blood clots had the highest proportions of White users, whereas type 2 diabetes and heart failure drugs had the highest proportions of Black users and beneficiaries residing in lower-income areas. Annual Part D OOP costs were lowest for sitagliptin (LIS: $104 [$60], non-LIS: $1,391 [$1,153]) and highest for ibrutinib (LIS: $649 [$649], non-LIS: $6,449 [$6,867]). Among non-LIS beneficiaries, 24% (22% to 76%) had more than $2,000 in OOP costs.

CONCLUSIONS:

Inflation Reduction Act OOP spending caps and LIS expansion will lower prescription drug costs for beneficiaries with OOP costs exceeding $2,000 who are mostly White and live in higher-income areas, insulin users who are disproportionately Black with multiple chronic conditions, and beneficiaries with low incomes. However, these provisions will not impact the 76% of non-LIS beneficiaries using negotiated drugs who have OOP costs that are still substantial but below $2,000. Negotiations could reduce OOP costs through reduced coinsurance payments for this group, which is older and has more chronic conditions compared with beneficiaries not taking negotiated drugs. Part D plan design, spending, and utilization changes should be monitored after negotiation to determine if further solutions are needed to lower OOP costs for this group.

1,267

项与伊布替尼相关的新闻（医药）

5 小时之前

·PRNewswire

Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and immunotherapies, such as Bruton's tyrosine kinase (BTK) inhibitors, is improving treatment outcomes and driving market growth for Mantle cell lymphoma. LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- DelveInsight's ' Mantle Cell Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mantle cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mantle cell lymphoma pipeline domain. Key Takeaways from the Mantle Cell Lymphoma Pipeline Report DelveInsight's mantle cell lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for mantle cell lymphoma treatment. Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape. Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials. In May 2024, AstraZeneca had announced positive interim results from the Phase III ECHO clinical trial, which evaluated Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in combination with standard chemoimmunotherapy for treating mantle cell lymphoma (MCL). In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting. Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma In October 2023, Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment. The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In January 2023, the FDA granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma (NHL), according to an announcement from Lantern Pharma. Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mantle cell lymphoma clinical trial landscape. Mantle Cell Lymphoma Overview Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by the (11,14) translocation, leading to overexpression of the cyclin D1 (CCND1) gene. Its various morphological variants can make diagnosis challenging, though some cases are straightforward. Many individuals with MCL are asymptomatic in the early stages, but may later seek medical attention due to persistent, typically painless swelling of lymph nodes, especially in the neck and throat region (e.g., Waldeyer's ring). MCL is marked by a reciprocal chromosomal translocation t(11;14)(q13;q32), which places the cyclin D1 gene next to the immunoglobulin heavy chain gene, causing continuous cyclin D1 expression. This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, chromosomal instability, and epigenetic changes. Rarely, MCL cases without this translocation may involve CCND2 or CCND3 translocations. Hypothetical molecular subtypes, based on the cell of origin, correlate with clinical phenotypes: classical or aggressive MCL arises from naive B cells lacking or having limited iGVH mutations and expressing SOX11, a neural transcription factor inhibiting terminal B cell differentiation. The indolent variant originates from antigen-experienced B cells with IGVH somatic hypermutations, typically SOX11-negative and genetically stable. Diagnosis of MCL involves detailed patient history, thorough clinical evaluation, and specialized tests, including biopsy of an affected lymph node or bone marrow. These tests confirm the NHL type and subtype, assess disease extent, and determine appropriate treatments. Treatment for MCL is multifaceted and tailored to each patient, often including chemotherapy, immunotherapy drugs like rituximab, targeted therapies such as ibrutinib, and stem cell transplants, particularly for aggressive disease or younger patients. Radiation therapy may target specific lymphoma areas. Participation in clinical trials can offer new treatment options. Treatment plans are developed collaboratively by healthcare professionals and patients, considering disease stage, overall health, and personal preferences. Regular monitoring and follow-up care are essential to track treatment response and manage side effects effectively. Find out more about mantle cell lymphoma treatment drugs @ Drugs for Mantle Cell Lymphoma Treatment A snapshot of the Mantle Cell Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging mantle cell lymphoma pipeline therapies @ Mantle Cell Lymphoma Clinical Trials Mantle Cell Lymphoma Therapeutics Assessment The mantle cell lymphoma pipeline report proffers an integral view of the mantle cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Mantle Cell Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Agammaglobulinemia tyrosine kinase inhibitors Key Mantle Cell Lymphoma Companies: AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others Key Mantle Cell Lymphoma Pipeline Therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others Dive deep into rich insights for new drugs for mantle cell lymphoma treatment, visit @ Mantle Cell Lymphoma Drugs Table of Contents For further information on the mantle cell lymphoma pipeline therapeutics, reach out @ Mantle Cell Lymphoma Treatment Drugs Related Reports B-Cell Lymphoma Epidemiology B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Pipeline Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期免疫疗法孤儿药

17 小时之前

·赛柏蓝

28个国产创新药，销售数据公布（附名单）

编者按：本文来自药智网，作者白纸扇；赛柏蓝授权转载，编辑相宜 01 28个国产创新药销售数据公布今年生物医药行业依旧艰难，但我们也看到越来越多创新药取得不错成绩，不少药企依靠销售创新药实现收入、利润双增。据统计，2018-2024年已有一百多个国产1类创新药获批上市。短短几年间，这些创新药在市场中大放异彩，多个品种半年销售额突破十亿，甚至有的逼近百亿大关。从企业已公布销售数据的品种来看，2024上半年30个创新药半年销售额合计224亿，较去年同期的130亿增长了73%。遗憾的是，还有众多药企未公布其具体品种的销售额详情，若能将这部分未公开的数据纳入统计范畴，这一数据将更可观。表1 2024上半年国产创新药销售情况（单位：亿元）注：仅统计了2018-2024年获批的国产1类创新药，不包括疫苗、中药、血液制品。从治疗领域来看，与国际市场不同，国产创新药畅销品种几乎都集中在抗肿瘤领域，在自身免疫性疾病、心血管和代谢领域等国外大品种盛行的领域都还未诞生大单品。非肿瘤领域，今年上半年仅华领医药的降糖药多格列艾汀销售额超过一亿元，当然也可能还有其他非肿瘤畅销品种，只是企业未公布销售数据。从具体靶点来看，畅销品种集中在PD-1、BTK、BCMA、EGFR等研发热门靶点，first in class靶点极少。从同比增速来看，大部分品种由于商业化时间尚短，正处于高速放量的迅猛增长期，展现出强劲的市场潜力与活力。然而，对于PD-1抗体这一细分领域而言，情况则显得更为复杂多变。由于该领域商业化进程相对较早，加之市场竞争的白热化，部分PD-1抗体品种已逐渐显现疲态，销售额出现了显著的下滑趋势，反映出市场饱和与竞争加剧的双重压力。另外，值得注意的是，越来越多国产创新药成功叩开美欧市场大门，并实现销售额爆发式增长。 02 掘金全球市场泽布替尼稳坐国产创新药“药王”宝座，2024上半年销售额11.26亿美元（人民币80.18亿元），同比增长122%。泽布替尼（中文商品名：百悦泽；英文商品名：BRUKINSA）是百济神州开发的一款BTK抑制剂。该药曾头对头击败伊布替尼，在治疗复发或难治性慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者的全球临床三期ALPINE试验上，取得无进展生存期（PFS）的优效性结果。此后，泽布替尼在CLL适应症快速放量。目前泽布替尼已在全球70个市场获批多项适应症，2023年实现销售额91亿元，而今年上半年销售额就已达到80亿元。分地区来看，美国销售额总计59.03亿元，占比74%；欧洲销售额总计10.57亿元，占比13%，且美欧地区增速都超过100%。泽布替尼在中国已获批六项适应症，其中五项适应症已纳入国家医保目录，但销售额只有8.73亿元，仅占总销售额11%，且同比增速也只有30.5%，远低于美欧地区。根据百济神州财报，截至今年6月底，泽布替尼胶囊累计投入70亿元，但今年上半年的销售收入就已超过了80亿元，投入虽高，但在高额销售收入面前一切都是值得的。排名第二的是传奇生物的西达基奥仑赛。与泽布替尼一样，该药的销售主战场也在海外。西达基奥仑赛（中文商品名：卡卫荻，英文商品名：Carvykti）是南京传奇生物开发的一种靶向BCMA的CAR-T疗法。该药于2022年2月首次在美国批准上市，同年5月获得欧盟EC授予的附条件上市许可，9月获得日本MHLW批准上市，用于治疗复发或难治性多发性骨髓瘤成人患者。2024年8月，该药终于在中国获批上市，用于治疗复发或难治性多发性骨髓瘤成人患者，既往接受过至少三线治疗后进展（至少使用过一种蛋白酶体抑制剂及免疫调节剂）。早在2017年，西达基奥仑赛凭借ORR（总缓解率）达到100%的早期临床数据获得强生青睐，向传奇生物支付3.5亿美元首期款及后续里程碑付款，共同开发和商业化cilta-cel，创下了当时中国药企对外专利授权首付款最大金额纪录及合作最优条件。 2023年西达基奥仑赛销售额达到5亿美元，2024上半年销售额3.43亿美元（人民币24亿元），同比增长82%，强生预计该药销售峰值将超过10亿美元。另外，和黄医药的呋喹替尼（爱优特，FRUZAQLA）也在美国取得了良好的销售成绩。呋喹替尼于2023年11月在美国上市，得益于合作伙伴武田制药的努力，该药今年上半年美国市场销售额达到1.305亿美元。加上呋喹替尼在中国市场销售的6100万美元，上半年销售额合计13.6亿元，同比去年的4亿，增长了240%。图片来源：和黄医药2024半年报 2024年6月，FRUZAQLA又获得欧盟委员会批准，还有十几个国家和地区也已提交上市许可申请，未来该药销售额有望进一步增长。 03 PD-1：几家欢喜几家愁自2018年首个国产PD-1上市以来，目前国产PD-(L)1抗体已有16款（包括单抗和双抗），严重内卷下，各家PD-(L)1抗体表现不一，几家欢喜几家愁。从已公布销售额的品种来看，百济神州的替雷利珠单抗（百泽安）是最畅销的国产PD-1，2024上半年销售额21.9亿元，同比增长19%，是唯一一个半年销售额超过20亿元的PD-1抗体。而且，替雷利珠单抗还于2023年9月和2024年3月相继在欧洲、美国市场获得监管批准上市，英文商品名：TEVIMBRA，销售额有望迎来新一轮的增长。排名第二的是信达生物的信迪利单抗（达伯舒），今年上半年实现销售收入2.397亿美元（人民币17亿元），同比增长46%，但是环比增速只有个位数。表2 2024上半年国产PD-(L)1抗体销售情况（单位：亿元）作为首个获批上市的国产PD-1抗体——君实生物的特瑞普利单抗销售额曾在2020年达到10亿元，但之后却从高处跌落，不过随着新适应症的获批，该药销售额又重新回到了增长轨道。特瑞普利单抗2024上半年销售额6.7亿元，同比增长50%，今年销售额预计将创新高。康方生物的两个PD-1双抗产品也表现优秀，卡度尼利单抗（开坦尼）上半年销售收入7.1亿元，同比增长17%。依沃西单抗（依达方）获批上市仅一个多月就发货了1亿多的销售额，而且该药在“头对头”对比帕博利珠单抗的随机对照大III期HARMONi-2研究中取得显著阳性结果，mPFS 11.14个月vs 5.82个月，赢得全球关注。如果能顺利在美国等海外市场获批，很可能成为下一个国产“十亿美元分子”。另外，复宏汉霖的斯鲁利单抗（汉斯状）、乐普生物的普特利单抗也在今年上半年实现了销售额增长。但是，在激烈的市场竞争中，恩沃利单抗、派安普利单抗及舒格利单抗几款产品已显现出增长疲态甚至下滑，未来命运如何，我们将继续观察。 04 结语国产创新药在支付环境相对不利的情况下，依然诞生了不少大品种，例如伏美替尼单个品种即可支撑艾力斯的营收、利润双增。还有部分创新药在海外市场披荆斩棘，泽布替尼半年销售额高达80亿元，西达基奥仑赛今年销售额预计也将超过50亿，可见走出国门参与全球竞争，才能破局销量天花板。近两年，国产创新药跨境license out交易繁荣，未来或有更多创新药在全球药品市场占据重要地位。 END 内容沟通：郑瑶（13810174402）医药代理商产品交流群扫描下方二维码加入医药代表交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

上市批准临床3期疫苗

23 小时之前

·药时代

国产创新药上半年销售“成绩单”出炉

今年生物医药行业依旧艰难，但我们也看到越来越多创新药取得不错成绩，不少药企依靠销售创新药实现收入、利润双增。据药智网统计，2018-2024年已有一百多个国产1类创新药获得获批上市。短短几年间，这些创新药在市场中大放异彩，多个品种半年销售额突破十亿，甚至有的逼近百亿大关。从企业已公布销售数据的品种来看，2024上半年30个创新药半年销售额合计224亿，较去年同期的130亿增长了73%。遗憾的是，还有众多药企未公布其具体品种的销售额详情，若能将这部分未公开的数据纳入统计范畴，这一数据将更可观。表1 2024上半年国产创新药销售情况（单位：亿元）注：仅统计了2018-2024年获批的国产1类创新药，不包括疫苗、中药、血液制品。数据来源：根据企业公开资料整理从治疗领域来看，与国际市场（2024H1全球畅销药TOP100）不同，国产创新药畅销品种几乎都集中在抗肿瘤领域，在自身免疫性疾病、心血管和代谢领域等国外大品种盛行的领域都还未诞生大单品。非肿瘤领域，今年上半年仅华领医药的降糖药多格列艾汀销售额超过一亿元，当然也可能还有其他非肿瘤畅销品种，只是企业未公布销售数据。从具体靶点来看，畅销品种集中在PD-1、BTK、BCMA、EGFR等研发热门靶点，first in class靶点极少。从同比增速来看，大部分品种由于商业化时间尚短，正处于高速放量的迅猛增长期，展现出强劲的市场潜力与活力。然而，对于PD-1抗体这一细分领域而言，情况则显得更为复杂多变。由于该领域商业化进程相对较早，加之市场竞争的白热化，部分PD-1抗体品种已逐渐显现疲态，销售额出现了显著的下滑趋势，反映出市场饱和与竞争加剧的双重压力。另外，值得注意的是，越来越多国产创新药成功叩开美欧市场大门，并实现销售额爆发式增长。掘金全球市场泽布替尼稳坐国产创新药“药王”宝座，2024上半年销售额11.26亿美元（人民币80.18亿元），同比增长122%。泽布替尼（中文商品名：百悦泽；英文商品名：BRUKINSA）是百济神州开发的一款BTK抑制剂。该药曾头对头击败伊布替尼，在治疗复发或难治性慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者的全球临床三期ALPINE试验上，取得无进展生存期（PFS）的优效性结果。此后，泽布替尼在CLL适应症快速放量。目前泽布替尼已在全球70个市场获批多项适应症，2023年实现销售额91亿元，而今年上半年销售额就已达到80亿元。分地区来看，美国销售额总计59.03亿元，占比74%；欧洲销售额总计10.57亿元，占比13%，且美欧地区增速都超过100%。泽布替尼在中国已获批六项适应症，其中五项适应症已纳入国家医保目录，但销售额只有8.73亿元，仅占总销售额11%，且同比增速也只有30.5%，远低于美欧地区。根据百济神州财报，截至今年6月底，泽布替尼胶囊累计投入70亿元，但今年上半年的销售收入就已超过了80亿元，投入虽高，但在高额销售收入面前一切都是值得的。排名第二的是传奇生物的西达基奥仑赛。与泽布替尼一样，该药的销售主战场也在海外。西达基奥仑赛（中文商品名：卡卫荻，英文商品名：Carvykti）是南京传奇生物开发的一种靶向BCMA的CAR-T疗法。该药于2022年2月首次在美国批准上市，同年5月获得欧盟EC授予的附条件上市许可，9月获得日本MHLW批准上市，用于治疗复发或难治性多发性骨髓瘤成人患者。2024年8月，该药终于在中国获批上市，用于治疗复发或难治性多发性骨髓瘤成人患者，既往接受过至少三线治疗后进展（至少使用过一种蛋白酶体抑制剂及免疫调节剂）。早在2017年，西达基奥仑赛凭借ORR（总缓解率）达到100%的早期临床数据获得强生青睐，向传奇生物支付3.5亿美元首期款及后续里程碑付款，共同开发和商业化cilta-cel，创下了当时中国药企对外专利授权首付款最大金额纪录及合作最优条件。 2023年西达基奥仑赛销售额达到5亿美元，2024上半年销售额3.43亿美元（人民币24亿元），同比增长82%，强生预计该药销售峰值将超过10亿美元。另外，和黄医药的呋喹替尼（爱优特，FRUZAQLA）也在美国取得了良好的销售成绩。呋喹替尼于2023年11月在美国上市，得益于合作伙伴武田制药的努力，该药今年上半年美国市场销售额达到1.305亿美元。加上呋喹替尼在中国市场销售的6100万美元，上半年销售额合计13.6亿元，较同比去年的4亿，增长了240%。图片来源：和黄医药2024半年报 2024年6月，FRUZAQLA又获得欧盟委员会批准，还有十几个国家和地区也已提交上市许可申请，未来该药销售额有望进一步增长。 PD-1：几家欢喜几家愁自2018年首个国产PD-1上市以来，目前国产PD-(L)1抗体已有16款（包括单抗和双抗），严重内卷下，各家PD-(L)1抗体表现不一，几家欢喜几家愁。从已公布销售额的品种来看，百济神州的替雷利珠单抗（百泽安）是最畅销的国产PD-1，2024上半年销售额21.9亿元，同比增长19%，是唯一一个半年销售额超过20亿元的PD-1抗体。而且，替雷利珠单抗还于2023年9月和2024年3月相继在欧洲、美国市场获得监管批准上市，英文商品名：TEVIMBRA，销售额有望迎来新一轮的增长。排名第二的是信达生物的信迪利单抗（达伯舒），今年上半年实现销售收入2.397亿美元（人民币17亿元），同比增长46%，但是环比增速只有个位数。表2 2024上半年国产PD-(L)1抗体销售情况（单位：亿元）数据来源：根据公开资料整理作为首个获批上市的国产PD-1抗体——君实生物的特瑞普利单抗销售额曾在2020年达到10亿元，但之后却从高处跌落，不过随着新适应症的获批，该药销售额又重新回到了增长轨道。特瑞普利单抗2024上半年销售额6.7亿元，同比增长50%，今年销售额预计将创新高。康方生物的两个PD-1双抗产品也表现优秀，卡度尼利单抗（开坦尼）上半年销售收入7.1亿元，同比增长17%。依沃西单抗（依达方）获批上市仅一个多月就发货了1亿多的销售额，而且该药在“头对头”对比帕博利珠单抗的随机对照大III期HARMONi-2研究中取得显著阳性结果，mPFS 11.14个月vs 5.82个月，赢得全球关注。如果能顺利在美国等海外市场获批，很可能成为下一个国产“十亿美元分子”。另外，复宏汉霖的斯鲁利单抗（汉斯状）、乐普生物的普特利单抗也在今年上半年实现了销售额增长。但是，在激烈的市场竞争中，恩沃利单抗、派安普利单抗及舒格利单抗几款产品已显现出增长疲态甚至下滑，未来命运如何，我们将继续观察。结语国产创新药在支付环境相对不利的情况下，依然诞生了不少大品种，例如伏美替尼单个品种即可支撑艾力斯的营收、利润双增。还有部分创新药在海外市场披荆斩棘，泽布替尼半年销售额高达80亿元，西达基奥仑赛今年销售额预计也将超过50亿，可见走出国门参与全球竞争，才能破局销量天花板。近两年，国产创新药跨境license out交易繁荣，未来或有更多创新药在全球药品市场占据重要地位。责任编辑 | 小月石封面图来源：123rf 版权声明/免责声明本文为授权转载文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 默沙东“首款” ADC III期研究结果公布，两名患者死亡！国家药品监督管理局：促进全球药物在中国同步研发、同步申报、同步审评、同步上市 | 附：报道视频同一天，三家美国biotech公司纳斯达克IPO，股价涨幅高达~50% 点击查看更多精彩！

临床3期疫苗上市批准

100 项与伊布替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10223	伊布替尼	L01XE27	DB09053

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
淋巴浆细胞性淋巴瘤	日本	Janssen Pharmaceutical KK	2022-12-23
移植物抗宿主病	日本	Janssen Pharmaceutical KK	2021-09-27
边缘区B细胞淋巴瘤	美国	Pharmacyclics LLC	2017-01-18
慢性移植物抗宿主病	墨西哥	Janssen-Cilag SA de CV	2015-03-01
小淋巴细胞淋巴瘤	墨西哥	Janssen-Cilag SA de CV	2015-03-01
难治性套细胞淋巴瘤	欧盟	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	冰岛	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	列支敦士登	Janssen-Cilag International NV	2014-10-21
难治性套细胞淋巴瘤	挪威	Janssen-Cilag International NV	2014-10-21
巨球蛋白血症	韩国	Janssen Korea Co. Ltd.	2014-08-08
慢性淋巴细胞白血病	美国	Pharmacyclics LLC	2014-02-12
套细胞淋巴瘤	美国	Pharmacyclics LLC	2013-11-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类固醇难治性移植物抗宿主病	临床3期	日本	Janssen Pharmaceuticals, Inc.	2018-05-01
慢性乙型肝炎	临床3期	中国香港	Janssen LP	2016-11-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	美国	Janssen Research & Development LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	美国	Pharmacyclics LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	比利时	Janssen Research & Development LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	比利时	Pharmacyclics LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	巴西	Pharmacyclics LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	巴西	Janssen Research & Development LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	保加利亚	Janssen Research & Development LLC	2016-07-01
难治性成熟B细胞非霍奇金淋巴瘤	临床3期	保加利亚	Pharmacyclics LLC	2016-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01724346 (CTgov)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	269	Next-line ibrutinib (Ibrutinib)	積遞齋積壓餘壓淵鹹遞(觸鬱鬱齋蓋壓膚糧範廠) = 蓋鹽醖鏇鑰齋積觸鹽膚鬱鹹醖鑰鹽範鬱襯簾淵 (鑰製襯製鹹壓衊憲範範, 醖鑰襯製夢繭蓋築壓窪 ~ 製壓膚願蓋膚鹽範壓廠) 更多	-	2024-09-19
				Ibrutinib (Chlorambucil)	積遞齋積壓餘壓淵鹹遞(觸鬱鬱齋蓋壓膚糧範廠) = 廠鏇鬱觸遞膚鹽鑰構觸鬱鹹醖鑰鹽範鬱襯簾淵 (鑰製襯製鹹壓衊憲範範, 齋願淵餘繭構壓願衊壓 ~ 膚觸積選範鹹鏇壓鹹願) 更多
NCT02477696 (ELEVATE-RR, Pubmed \| Blood)	临床3期	慢性淋巴细胞白血病 BTK mutations \| TP53 mutations \| PLCG2 mutations	-	Acalabrutinib-treated patients	廠鏇衊鑰願憲鑰膚鹹鏇(網壓鬱夢網鹹繭齋糧膚) = 網蓋製膚襯鬱鹹遞艱遞築夢糧糧觸積繭製膚繭 (顧淵鹽鏇鬱製鑰窪網窪 ) 更多	-	2024-09-05
				Ibrutinib-treated patients	廠鏇衊鑰願憲鑰膚鹹鏇(網壓鬱夢網鹹繭齋糧膚) = 夢製餘鏇艱遞積獵鏇醖築夢糧糧觸積繭製膚繭 (顧淵鹽鏇鬱製鑰窪網窪 ) 更多
NCT02315326 (Pubmed) 人工标引	临床2期	继发性中枢神经系统淋巴瘤 \| 原发性中枢神经系统淋巴瘤 circulating tumor DNA	46	Ibrutinib (PCNSL)	繭餘淵膚築蓋憲醖遞醖(選艱鬱選壓願簾糧觸範) = 構鬱願鏇壓齋廠鏇獵夢壓鹽夢襯夢網醖鹹獵鹽 (獵構繭壓憲廠廠選齋蓋, 2.8 ~ 9.2) 更多	积极	2024-07-12
				Ibrutinib (SCNSL)	繭餘淵膚築蓋憲醖遞醖(選艱鬱選壓願簾糧觸範) = 構獵製齋齋簾淵願鏇憲壓鹽夢襯夢網醖鹹獵鹽 (獵構繭壓憲廠廠選齋蓋, 1.3 ~ 14.5) 更多
NCT03939182 (NEWS) 人工标引	临床1期	套细胞淋巴瘤	-	艾贝司他，伊布替尼	願製廠蓋願顧憲製選構(積構範鏇願網蓋鑰鹹觸) = 艾贝司他联合伊布替尼有效率（CR和ORR）及无进展生存期（PFS）均优于单独使用伊布替尼願衊鏇構網糧齋顧艱鹹 (艱窪簾衊鏇選壓鏇網糧 )	积极	2024-06-28
				伊布替尼
NCT03112174 (SYMPATICO, ASCO2024) 人工标引	临床3期	套细胞淋巴瘤一线 TP53 Mutation	74	Ibrutinib + Venetoclax (first-line (1L) + without TP53 mutations)	窪壓製繭遞積餘夢襯襯(淵鹹餘選壓鬱網艱構願) = 構憲艱遞構願壓餘餘簾壓淵醖醖膚願築醖鑰鏇 (積夢顧築觸簾憲醖餘願, NE–NE) 更多	积极	2024-05-24
				Ibrutinib + Venetoclax (relapsed/refractory (R/R) + without TP53 mutations)	築遞網繭繭鹹壓鏇衊觸(選鏇觸壓衊鬱積鹹憲艱) = 願膚築窪簾繭糧鏇蓋觸觸遞簾醖築簾憲願衊淵 (構鹹鬱醖製鹹廠衊鬱繭 ) 更多
NCT02910583 (CAPTIVATE, ASCO2024) 人工标引	临床2期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线 del(17p) \| mutatedTP53 \| complex karyotype ... 更多	202	Ibrutinib + Venetoclax (With high-risk genomic feature)	願壓壓鹽餘鹹餘鹽繭鹹(窪廠積獵製衊顧醖簾鹽) = 壓鏇醖糧壓壓醖積壓艱夢築觸憲鏇襯淵壓選廠 (蓋構蓋窪憲選艱襯鬱襯, 21 ~ 59) 更多	积极	2024-05-24
				Ibrutinib + Venetoclax (Without high-risk genomic feature)	願壓壓鹽餘鹹餘鹽繭鹹(窪廠積獵製衊顧醖簾鹽) = 範鹹餘遞繭範淵範艱鏇夢築觸憲鏇襯淵壓選廠 (蓋構蓋窪憲選艱襯鬱襯, 64 ~ 80) 更多
NCT03190330 (CTgov)	临床4期	B细胞白血病 \| 套细胞淋巴瘤 \| 慢性淋巴细胞白血病 ... 更多	75	Ibrutinib 560 mg	醖鹹鬱願範遞餘獵製憲(壓餘範醖鏇遞鏇壓壓餘) = 鬱製糧憲憲鏇鹹齋夢繭願鹹衊蓋艱鹹齋蓋齋願 (製鏇選構製簾顧範壓廠, 遞範構憲積構鑰製鏇廠 ~ 鏇觸築壓獵襯窪鬱築獵) 更多	-	2024-05-21
NCT02956382 (PHASE IB/II STUDY OF IBRUTINIB AND VENETOCLAX IN RELAPSED AND REFRACTORY FOLLICULAR LYMPHOMA, CTgov)	临床1/2期	复发性滤泡性淋巴瘤 \| 难治性滤泡性淋巴瘤	24	Ibrutinib+Venetoclax (Phase I - Dose Level 0)	齋淵醖糧淵夢艱觸願獵(簾衊獵遞淵積壓衊製願) = 範鹽夢積餘網醖鏇淵襯網觸製憲衊衊窪壓鹹窪 (願醖醖憲顧糧淵製窪壓, 廠遞願積壓衊壓選淵遞 ~ 艱鏇網鹽網襯糧簾鑰簾)	-	2024-05-21
				Ibrutinib+Venetoclax (Phase I - Dose Level 1)	齋淵醖糧淵夢艱觸願獵(簾衊獵遞淵積壓衊製願) = 選淵壓蓋顧網淵醖餘艱網觸製憲衊衊窪壓鹹窪 (願醖醖憲顧糧淵製窪壓, 鏇壓鹽蓋選願醖築糧壓 ~ 襯構獵築蓋積餘憲糧願)
NCT03734016 (ALPINE, EHA2024) 人工标引	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤 BTK	648	Zanubrutinib	繭齋範鹹蓋壓蓋襯壓鏇(遞構構範餘艱簾鹹淵積) = 艱鏇憲顧鑰醖獵膚鏇顧廠顧獵選蓋廠窪窪鏇願 (製夢齋選鏇顧餘壓構淵 ) 更多	积极	2024-05-14
				Ibrutinib	繭齋範鹹蓋壓蓋襯壓鏇(遞構構範餘艱簾鹹淵積) = 蓋糧顧構鏇積鑰醖遞遞廠顧獵選蓋廠窪窪鏇願 (製夢齋選鏇顧餘壓構淵 ) 更多
NCT01722487 (RESONATE-2, EHA2024) 人工标引	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线 del(17p)	269	Ibrutinib	獵襯構窪鏇鹹糧憲網顧(糧構窪積選壓構蓋鏇鹽) = 繭網鬱製構壓觸艱製願壓淵淵鑰構衊襯窪夢鏇 (衊艱夢鑰繭範鑰夢觸壓, 7.0 ~ NE) 更多	积极	2024-05-14
				Chlorambucil	獵襯構窪鏇鹹糧憲網顧(糧構窪積選壓構蓋鏇鹽) = 範夢鬱糧製醖蓋繭蓋觸壓淵淵鑰構衊襯窪夢鏇 (衊艱夢鑰繭範鑰夢觸壓, 0.9 ~ 1.6)